Leukemia is a malignancy of the hematopoietic system, and as its pathogenesis has
become better understood, three generations of tyrosine kinase inhibitors (TKIs) have been …

With the progression of tumor treatment, the 5-year survival rate of breast cancer is close to
90%. Cardiovascular toxicity caused by chemotherapy has become a vital factor affecting …

Low‐dose dasatinib is safe and effective in patients with chronic myeloid leukemia in
chronic phase (CML‐CP). No randomized trials have compared the outcome with standard …

Several research and market developments in the past 5 years could influence front-line and
subsequent-line strategies in chronic myeloid leukaemia. These developments include the …

Simple Summary Tyrosine kinase inhibitors (TKIs) are the main class of drugs used to treat
chronic myeloid leukemia. Because most CML patients must remain on TKIs indefinitely, it is …

The BCR:: ABL1 tyrosine kinase inhibitors (TKIs) have improved the outcomes of patients
with chronic myeloid leukemia (CML). After failing second‐generation TKI (2G‐TKI), the …

Accumulating evidence indicates that the anticancer activity of acridine derivatives is
mediated through the regulation of anti-apoptotic and pro-apoptotic BCL2 protein …

Acute myeloid leukemia (AML) with BCR:: ABL1 has recently been recognized as a distinct
subtype in international classifications. Distinguishing it from myeloid blast crisis chronic …

Over the past several years, advances in research, treatment, and market dynamics have
impacted treatment strategies in chronic myeloid leukemia in chronic phase (CML-CP). They …

Background Since the introduction of BCR:: ABL1 tyrosine kinase inhibitors (TKIs) in 2000,
the treatment of Philadelphia chromosome (Ph)‐positive chronic myeloid leukemia (CML) …